Format

Send to

Choose Destination
Br J Dermatol. 2018 Oct 22. doi: 10.1111/bjd.17341. [Epub ahead of print]

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases.

Author information

1
Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
2
Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
3
Department of Anaesthesiology Pain Center, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Abstract

Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain care in EB; however, they are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been studied increasingly for pain conditions of various aetiologies and pose as a novel dimension for pain care in EB. We present three patients with EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol and cannabidiol. All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake.

PMID:
30347109
DOI:
10.1111/bjd.17341

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center